share_log

Weak Statutory Earnings May Not Tell The Whole Story For Shanghai No.1 PharmacyLtd (SHSE:600833)

Weak Statutory Earnings May Not Tell The Whole Story For Shanghai No.1 PharmacyLtd (SHSE:600833)

疲软的法定收入可能无法说明上海第一制药有限公司(SHSE: 600833)的全部情况
Simply Wall St ·  04/05 18:03

A lackluster earnings announcement from Shanghai No.1 Pharmacy Co.,Ltd. (SHSE:600833) last week didn't sink the stock price. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.

上海第一制药股份有限公司发布的财报乏善可陈, Ltd.(上海证券交易所代码:600833)上周没有使股价下跌。我们的分析表明,除了疲软的利润数字外,投资者还应意识到这些数字中的其他一些潜在弱点。

earnings-and-revenue-history
SHSE:600833 Earnings and Revenue History April 5th 2024
SHSE: 600833 2024 年 4 月 5 日的收益和收入历史记录

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

To properly understand Shanghai No.1 PharmacyLtd's profit results, we need to consider the CN¥92m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And, after all, that's exactly what the accounting terminology implies. We can see that Shanghai No.1 PharmacyLtd's positive unusual items were quite significant relative to its profit in the year to December 2023. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

为了正确理解上海第一制药有限公司的利润业绩,我们需要考虑不寻常项目带来的9.2亿元人民币的收益。我们不能否认更高的利润通常会让我们感到乐观,但如果利润是可持续的,我们更愿意这样做。我们统计了全球大多数上市公司的数字,不寻常的物品在自然界中很常见。而且,毕竟,这正是会计术语的含义。我们可以看到,截至2023年12月的一年中,上海第一制药有限公司的正面不寻常项目与其利润相比相当可观。在其他条件相同的情况下,这可能会使法定利润成为衡量潜在盈利能力的不良指导。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Shanghai No.1 PharmacyLtd.

注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对上海第一制药有限公司的资产负债表分析

Our Take On Shanghai No.1 PharmacyLtd's Profit Performance

我们对上海第一制药有限公司盈利表现的看法

As previously mentioned, Shanghai No.1 PharmacyLtd's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that Shanghai No.1 PharmacyLtd's underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 29% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example - Shanghai No.1 PharmacyLtd has 2 warning signs we think you should be aware of.

如前所述,上海第一制药有限公司从不寻常项目中获得的巨大提振不会无限期地存在,因此其法定收益可能无法很好地指导其潜在盈利能力。因此,我们认为上海第一制药有限公司的基础盈利能力很可能低于其法定利润。但是,至少持有人可以从过去三年的每股收益每年增长29%中得到一些安慰。当然,我们只是在分析其收益时才浮出水面;人们还可以考虑利润率、预测增长和投资回报率等因素。因此,如果你想更深入地研究这只股票,那么考虑它面临的任何风险至关重要。例如,上海第一制药有限公司有两个警告标志,我们认为你应该注意。

Today we've zoomed in on a single data point to better understand the nature of Shanghai No.1 PharmacyLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我们放大了单一数据点,以更好地了解上海第一制药有限公司利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多的事情需要发现。例如,许多人认为高股本回报率是有利的商业经济的标志,而另一些人则喜欢 “关注资金”,寻找内部人士正在买入的股票。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发